Previous 10 | Next 10 |
Channelchek news releases related Channelchek news releases and Channelchek press releases from 04/04/22 12:00:00 on US and Canada Markets.
Onconova Presented Data At The Next Generation Kinase Inhibitors Summit. Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information ...
Filament Made Substantial Progress During 4Q21. Filament Health reported a full year loss of $9.3 million or $(0.06) per share. During the quarter, Filament advanced its clinical pipeline, made licensing agreements, and strengthened its intellectual property. The cash balance at December 31, 2...
Subscribers Growing. Although management did not provide a current subscriber count, as management wants to see the stickiness of a recent marketing campaign before providing numbers, management did state the trajectory of subscriber growth is on track and they are pleased with subscriber grow...
Initiating Coverage. We are initiating research coverage on GABY Inc. with an Outperform rating and a $0.05 12-month price target. GABY Inc. is a California-focused cannabis retail consolidator and the owner of San Diego-based Mankind Dispensary, one of the oldest and largest licensed dispensa...
Subscribers Growing. Although management did not provide a current subscriber count, as management wants to see the stickiness of a recent marketing campaign before providing numbers, management did state the trajectory of subscriber growth is on track and they are pleased with subscriber grow...
Ocugen Meets A Pipeline Milestone Ocugen announced treatment of the first patient in its Phase 1/2 trial for OCU400, the first product from its gene therapy platform to reach clinical trials. OCU400 delivers genes to correct the genetic mutations that lead to retinitis pigmentosa, an ophthalmi...
Resignation announced. Chairman of the Board of Directors Alfred Altomari announced March 30, 2022, that he was intending to resign. Mr. Altomari has been a director at Baudax Bio since 2019, and was a prior member of the Recro Pharma Board (Recro spun out Baudax Bio to shareholders in 2019). ...
4Q21 Results. Revenue for the quarter totaled $26.5 million, up from $7.9 million a year ago, but down from $31.8 million in the third quarter. The sequential drop was due to overall softness in cannabis in Colorado during the quarter, both on the retail and wholesale level. Adjusted EBITDA wa...
1Q21 Results. Revenue for the fiscal first quarter ended February 28th was $117.1 million, up 15.9% y-o-y. Wholesale revenue rose 19% to $83.5 million, while Retail revenue rose 3.7% to $64.1 million. Bassett reported net income from continuing operations of $4.3 million, or $0.44 per share, c...
Q4 2021 reported. Yesterday, BioSig Technologies reported their fourth quarter, missing on top-line expectations, with no unit sales reported. That said, the company continues to roll out a phased commercialization strategy to promote faster revenue growth longer term. Recent hires are expecte...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.06%Change Percent:
Biogen Inc. Company Name:
BIIB Stock Symbol:
NASDAQ Market:
biogen.com Website: